A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Hallett, Robin M ^a   Pond, Gregory ^b   Hassell, John A ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Breast cancer; Chemotherapy; Chemotherapy response; Gene expression profiling; Gene signatures

Indexed keywords

ANTHRACYCLINE; BETA TUBULIN; DOCETAXEL; ESTROGEN RECEPTOR; PACLITAXEL; TAXANE DERIVATIVE; TOP2A PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RNA, MESSENGER; TAXOIDS; TREATMENT OUTCOME; TUBULIN;

EID: 84860800968     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-16     Document Type: Article

References (16)

1. Efficacy and safety of trastuzumab as a single agent in first- line treatment of HER2-overexpressing metastatic breast cancer. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al. J Clin Oncol 2002 20 3 719 726 10.1200/JCO.20.3.719 11821453 (Pubitemid 34111379)
2. A gene-expression signature as a predictor of survival in breast cancer. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. N Engl J Med 2002 347 25 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
3. Gene expression profiling predicts clinical outcome of breast cancer. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Nature 2002 415 6871 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
4. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. N Engl J Med 2004 351 27 2817 2826 10.1056/NEJMoa041588 15591335 (Pubitemid 40051905)
5. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al. J Clin Oncol 2006 24 23 3726 3734 10.1200/JCO.2005.04.7985 16720680 (Pubitemid 46622311)
6. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. J Natl Cancer Inst 2006 98 4 262 272 10.1093/jnci/djj052 16478745 (Pubitemid 43264710)
7. An algorithm to discover gene signatures with predictive potential. Hallett RM, Dvorkin A, Gabardo CM, Hassell JA, J Exp Clin Cancer Res 2010 29 1 120 10.1186/1756-9966-29-120 20813028
8. E2F1 and KIAA0191 expression predicts breast cancer patient survival. Hallett RM, Hassell JA, BMC Res Notes 2011 4 95 10.1186/1756-0500-4-95 21453498
9. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. J Clin Oncol 2006 24 26 4236 4244 10.1200/JCO.2006.05.6861 16896004 (Pubitemid 46630780)
10. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, Baggerly K, Rouzier R, Pusztai L, Clin Cancer Res 16 2 711 718
11. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al. Clin Cancer Res 11 358 365
12. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, et al. J Clin Oncol 2010 28 18 2982 2988 10.1200/JCO.2009.26.5900 20479410
13. Lapatinib. Moy B, Kirkpatrick P, Kar S, Goss P, Nat Rev Drug Discov 2007 6 6 431 432 10.1038/nrd2332 17633789 (Pubitemid 47064564)
14. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP, Biostatistics 2003 4 2 249 264 10.1093/biostatistics/4.2.249 12925520
15. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, et al. Science 1999 286 5439 531 537 10.1126/science.286.5439.531 10521349
16. A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer. Hallett RM, Dvorkin-Gheva A, Anita B, Hassell JA, Sci Rep 2012 2 227 22355741